CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Assessment by baseline HbA1c of key outcomes for once weekly dulaglutide versus insulin glargine, both with prandial insulin lispro, in patients with type 2 diabetes from the Assessment of Weekly AdministRation of dulaglutide in Diabetes 4…
DOI 10.1055/s-0035-1549747
Bibliografische Angaben
Nachweis in CareLit
Autor:innenO Adetunji, H Jung, N Jia, Z Milicevic
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Post-hoc subgroup analysis by baseline HbA1c investigating the efficacy and safety of once-weekly dulaglutide and daily insulin glargine in patients with T2DM, all receiving prandial insulin lispro (± metformin). Methods: Efficacy and safety data from patients receiving dulaglutide 1.5 mg (N = 293), dulaglutide 0.75 mg (N = 291) or insulin glargine (N = 291) were compared at 26 weeks within each baseli…
Zitieren
Zitierempfehlung
O Adetunji, H Jung, N Jia, Z Milicevic (2015) Assessment by baseline HbA1c of key outcomes for once weekly dulaglutide versus insulin glargine, both with prandial insulin lispro, in patients with type 2 diabetes from the Assessment of Weekly AdministRation of dulaglutide in Diabetes 4 (AWARD-4) study. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0035-1549747
Mit CareLit weiterarbeiten